Larsson M, Castren M, Lindström V, et al. - Given that glucagon like peptide-1 receptor agonists (GLP-1RA) are medicines used in T2D that have a low risk of hypoglycemia and have been shown to have neuroprotective impacts, researchers ascertained if GLP-1RA exenatide prehospital administration could reduce plasma glucose in patients with strokes, as well as analyzed tolerability and safety. For this investigation, they randomized patients (n = 19) with Face Arm Speech Test ≥ 1 and glucose ≥ 8 mmol/L. No evidence was found that hyperglycemia was affected by prehospital exenatide. However, it was given in this study with a limited sample size without adverse events, which was stopped prematurely due to slow inclusion.